GYPC and lassa virus infectious disease: Three of the antibodies for which we mapped escape (12.1F, 37.2D, and 8.9F) are being developed as an antibody cocktail called Arevirumab-3,29 which protects from lethal Lassa virus infection in animal models.29–32 To provide insight into how GPC mutations could affect neutralization by the antibodies in this cocktail, we analyzed the escape maps for mutations that reduced neutralization by multiple antibodies in the cocktail (Figure S8).